GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/Comprehensive Genomic Profiling in GI Cancers: JCO Precision Oncology | August 2026
9

Comprehensive Genomic Profiling in GI Cancers: JCO Precision Oncology | August 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated August 1, 2026

Introduction:

Comprehensive genomic profiling (CGP) is increasingly used in gastrointestinal cancers to identify actionable molecular alterations and guide precision therapy. However, its real-world value depends not only on detecting a target but also on whether patients can actually access the matched treatment. This study evaluated CGP performance and clinical impact in a large comprehensive cancer center.

Why was this study needed?

CGP can identify therapeutic targets missed by routine molecular testing.

Its real-world technical success and clinical benefit remain uncertain.

Tissue quality can limit successful genomic profiling.

Even when actionable alterations are detected, access to matched therapy remains challenging.

Results:

Among 1,450 samples, approximately 10% failed CGP, predominantly because of inadequate tumor DNA.

Among metastatic patients, 28% had actionable genomic alterations, but only about 16% of these patients received matched targeted therapy.

Patients receiving genomically matched therapy had substantially longer survival (26.4 months) than those with actionable alterations who did not receive matched treatment.

Among untreated patients with actionable alterations, lack of suitable clinical trials or trial ineligibility was a major barrier to precision treatment.

Clinical Impact:

CGP can translate into meaningful clinical benefit in GI oncology—but only when an actionable finding leads to treatment. The study emphasizes early genomic testing at diagnosis of advanced disease, careful tissue selection, multidisciplinary molecular tumor boards, and better access to clinical trials and targeted therapies.

Bottom Line:

Comprehensive genomic profiling identified actionable alterations in more than one-quarter of metastatic GI cancers, and patients who received matched therapy had markedly better survival. The major challenge is no longer simply finding the target—it is ensuring that patients can access the treatment.

Related Q&A

10

Lynch Syndrome Surveillance Works—but One-Third of Cancers Occur Outside Current Protocols: ESMO Gastrointestinal Oncology | August 2026

Introduction: Lynch syndrome carries a lifelong risk of developing cancers across multiple organs. While colorectal surveillance is well established, the effectiveness of broader multiorgan surveillance remains less certain....

11

Durvalumab–Gemcitabine–Cisplatin (TOPAZ-1) Remains Effective in Real-World Biliary Tract Cancer: IJC | August 2026

Introduction: Durvalumab plus gemcitabine–cisplatin (CGD) is standard first-line therapy for advanced biliary tract cancer (BTC) based on TOPAZ-1. However, clinical trials exclude many patients encountered in everyday practice....

12

Tumour-Negative Lymph Node Size Emerges in Oesophagogastric Cancer: ESMO Gastrointestinal Oncology | August 2026

Introduction: Lymph node metastasis is a major prognostic factor in oesophagogastric adenocarcinoma (OGAC), but tumour-negative lymph nodes (LNneg) have received little attention. This analysis of two major Phase...

13

iDREM-BTC: Dynamic Biomarker Monitoring Enables Real-Time Prognosis in Advanced Biliary Tract Cancer: Journal of Hepatology | 2026

Introduction: First-line immunochemotherapy is now standard for advanced biliary tract cancer (BTC), but treatment responses vary widely. Most prognostic models rely on baseline information, ignoring how patients evolve...

14

NETTER-2: ¹⁷⁷Lu-DOTATATE in Higher-Grade GEP-NETs: The Lancet Oncology | August 2026

Introduction: The Phase III NETTER-2 trial established ¹⁷⁷Lu-DOTATATE plus octreotide as an effective first-line therapy for advanced, well-differentiated, somatostatin receptor (SSTR)-positive higher-grade G2–G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This...

15

Do Men and Women Respond Differently to Immunotherapy in Advanced Oesophagal Squamous Cell Carcinoma: ESMO Gastrointestinal Oncology | August 2026

Introduction: The combination of chemotherapy and immune checkpoint inhibitors (ICIs) is now the standard first-line treatment for advanced oesophagal squamous cell carcinoma (ESCC). Emerging evidence from several cancers...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer